Beijing’s CANbridge brings on Pfizer rare disease leader as CMO to help bring new drugs to China

China-US tariff war
CANbridge plans to develop and commercialize Puma's Nerlynx and Apogenix's APG101 as cancer treatments in China. (iStock)

Beijing’s CANbridge Life Sciences, which develops Western drug candidates in China and Asia, brought on Pfizer’s May Orfali, M.D., to be its new chief medical officer.

Orfali, based in Cambridge, Massachusetts, most recently served as the Big Biotech’s executive director of global product development in rare diseases, covering hematology, sickle cell disease, hemophilia, endocrinology, gene therapy and TTR-amyloidosis.

Before that, she was a rare disease lead for Pfizer’s global innovative pharmaceutical business unit, a global medical asset lead in hematology, and a senior director of clinical R&D in medical oncology. She replaces Mark Goldberg, M.D., who has served as acting CMO since 2015, and will stay on as an advisor.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

“We are delighted that Dr. Orfali has chosen to join CANbridge as we become a fully-commercial biopharmaceutical company with a robust clinical trial program and pipeline,” said CANbridge’s chairman and CEO, James Xue, Ph.D.

Prior to Pfizer, Orfali held clinical leadership positions at Wyeth Pharmaceutical, Artisan Pharma, Aeris Therapeutics, Cubist Pharmaceuticals and Boston Scientific.

“Her broad international experience, and proven track record of clinical trial success in multiple indications, will be key as CANbridge continues to advance our world-class programs in oncology and orphan-designated diseases, particularly in those that are severely underserved in China and Asia,” Xue said in a statement.

RELATED: China’s CANbridge Life Sciences gains $25M series B, plots new cancer trials

In February, CANbridge signed an exclusive licensing agreement with Puma Biotechnology to commercialize Nerlynx (neratinib) in China, Taiwan, Hong Kong and Macao.

Nerlynx tablets were approved by the FDA in July 2017 for extended adjuvant treatment in HER2-positive breast cancer following Herceptin-based therapy, and CANbridge is developing the drug as CAN030 in HER2-positive breast and gastric cancers.

CANbridge also maintains a license with Apogenix to develop and commercialize its immuno-oncology therapy APG101, retitled as CAN008, for glioblastoma multiforme. CANbridge expects to begin a phase 2/3 trial later this year.

In addition, CANbridge has a worldwide license, outside of North America, to AVEO Oncology’s clinical-stage ErbB3 inhibitor antibody candidate AV203, named CAN017—and an agreement with EUSA Pharma to commercialize Caphosol, approved in China for oral mucositis caused by cancer treatments.

Suggested Articles

Cold Genesys is developing its lead asset as a single agent and in combination therapies and has taken it through phase 2 in bladder cancer.

Dermira has generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Regeneron and Sanofi’s Dupixent.

Shares in Aerpio Pharmaceuticals were more than halved in early trading this morning after it announced the failure of its leading drug candidate.